Posted by Michael Wonder on 27 Feb 2024
Tafamidis for the treatment of patients with transthyretin amyloidosis with cardiomyopathy
27 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of tafamidis in the NHS in England.
For the time being, tafamidis is not recommended for the treatment of adults with wild type or hereditary transthyretin amyloidosis with cardiomyopathy.
